

## References

I-118

1. Ziemssen T, DeStefano N, Sormani M, et al. Optimizing therapy early in Multiple Sclerosis: An evidence-based view. *Multiple Sclerosis and Related Disorders*. 2015;4:460–469.
2. Rachel, B, Perumal JS. Comparative efficacy of alemtuzumab and established treatment in the management of multiple sclerosis. *Neuropsychiatric Disease and Treatment*. 2015;11:1221– 1229.
3. Giovannoni G, Cohen JA, Hartung HP, et al. Alemtuzumab improves preexisting disability in active relapsing-remitting MS patients. 2016;87.
4. Fox EJ, Wynn D, Coles AJ, et al. Alemtuzumab improves neurological functional systems in treatment-naive relapsing-remitting multiple sclerosis patients. *Journal of the Neurological Sciences*. 2016;188–194.
5. MICROMEDEX®SOLUTIONS Compendia. 2019. Alemtuzumab.
6. Clinical Pharmacology Compendia. [database online]. Tampa FL: Gold Standard, Alemtuzumab. 2019.
7. Merino AG, Ara Callizo JR, Fernandez OF, et al. Consensus statement on the treatment of multiple sclerosis by the Spanish Society of Neurology in 2016. 2017;113-119.
8. Lemtrada (Alemtuzumab) injection, for intravenous use [package insert]. Genzyme Corporation. Cambridge, MA. Revised 01/2019.
9. Dörr J, Baum K. Alemtuzumab in the treatment of multiple sclerosis: patient selection and special considerations. *Drug Des Devel Ther*. 2016;10:3379–3386.
10. Coles AJ, Cohen JA, Fox EJ, et al. Alemtuzumab CARE-MS II 5-year follow-up: Efficacy and safety findings. *Neurology*. 2017;89(11):1117–1126.
11. Thompson AJ, Banwell BL, Barkhof F, et al. Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. *The Lancet*. 2018. 17(2):162-173.